Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012)
Johnson & Johnson's (JNJ) quarterly Land & Improvements came in at $754.0 million in Q1 2012, up 2.17% year-on-year from $738.0 million in Q1 2011, and up 2.17% quarter-over-quarter from $738.0 million in Q1 2011.
Johnson & Johnson (JNJ) Land & Improvements (2011 - 2012) Analysis & Trends
Johnson & Johnson has disclosed Land & Improvements across 2 years of filings, most recently posting $754.0 million for Q1 2012.
- Land & Improvements for Q1 2012 came in at $754.0 million, up 2.17% year-over-year; the trailing twelve-month figure through Jan 2012 was $754.0 million (up 2.17% YoY), and the FY2012 annual result was $754.0 million, up 2.17% from the prior year.
- Land & Improvements came in at $754.0 million for Q1 2012 at Johnson & Johnson, up from $738.0 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $754.0 million in Q1 2012 to a low of $738.0 million in Q1 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 1, 2012 | 754.00 Mn |
| Jan 2, 2011 | 738.00 Mn |